Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. HALO announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37^th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.

SABCS Poster Presentation Details

Title: "Hyaluronan Depletion Sensitizes HA^high Tumors to Antibody-Dependent Cell-Mediated Cytotoxicity"
Poster Session: P5-04-02, December 12, 2014, 7:00AM - 7:00PM CDT
Location: Exhibit Hall A-B
Summary: About 50% of HER2⁺³ breast cancers and 12% of ovarian cancers accumulate abundant HA in the tumor microenvironment. The accumulation of HA is known to result in decreased access of therapeutics to the tumor.  Therefore, HA accumulation may contribute to trastuzumab resistance. When HA is depleted by treatment with PEGPH20 in vitro, HA^high/HER2⁺³ cells become much more sensitive to antibody-mediated cellular cytotoxicity. Additionally, HA^high/HER2⁺³ human tumors in mice treated with PEGPH20 increased the access of trastuzumab and immune cells to the tumor, resulting in enhanced antitumor activity. These results suggest that co-administration of PEGPH20 could enhance the efficacy of trastuzumab in HA^high/HER2⁺³ tumors.

Title: "Naked Mole Rat HAS2 and Hyaluronan Are Not Tumor Suppressive in Human Tumor Xenografts"
Poster Session: P4-04-25, December 12, 2014, 7:00AM - 7:00PM CDT
Location: Exhibit Hall A-B
Summary:  Published third-party literature suggests that naked mole rat hyaluronan synthase 2 (nmrHAS2) produces extraordinarily high molecular weight HA, which has tumor suppressive effects. Transfection of the nmrHAS2 gene into human tumor cells did not suppress the growth of human tumors in nude mice and suggests that HA in the naked mole rat may have different functions than in human cancer, where HA accumulation promotes tumor growth.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The company markets Hylenex^® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 10, 2014.

Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com

Media Contact:
Susan Neath Francis
212-301-7182
sfrancis@wcgworld.com

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-announces-presentations-of-preclinical-data-at-the-san-antonio-breast-cancer-symposium-annual-meeting-300008905.html

SOURCE Halozyme Therapeutics, Inc.